

(DRAFT/UNAPPROVED)

**VIRGINIA BOARD OF PHARMACY
MINUTES OF PUBLIC HEARING ON PLACING CERTAIN CHEMICALS INTO
SCHEDULE I**

Tuesday, June 16, 2026

Department of Health Professions
Perimeter Center
Board Room 2
9960 Mayland Drive
Henrico, Virginia 23233

CALL TO ORDER: A public hearing regarding the placement of 6 chemicals into Schedule I per recommendation from the Department of Forensic Science was convened at 9:00 AM.

PRESIDING: **Larry Kocot, JD, Chairman**

MEMBERS PRESENT: **Jay Agarwal, RPh**
Shannon Dowdy, PharmD, Vice Chairman
Kelly Hasty Kale, RPh
Jade Ranger, PharmD
Kristopher Ratliff, DPh
Patricia Richards-Spruill, RPh
Derek Webb, PharmD
Ling Yuan, PharmD

MEMBER ABSENT: **Michelle Hoffer Wilgus, JD**

STAFF PRESENT: **Erin Barrett, DHP Director of Legislative and Regulatory Affairs**
David E. Brown, DHP Director
Mykl Egan, Discipline Case Manager
Sorayah Haden, Executive Assistant
Caroline Juran, RPh, Executive Director
Ryan Logan, RPh, Deputy Executive Director
Tim Reilly, Compliance and Innovative Pilot Program Manager
Brent Saunders, JD, Senior Assistant Attorney General

PUBLIC COMMENT Robyn Weimer, Chemistry Program Manager, Division of Technical Services, Virginia Department of Forensic Science provided comment that the recommended 6 chemicals listed below are a risk to public safety and do not serve a known medical use.

- 1. 3-[2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol (other names: O-desmethyltramadol, ODMT), its isomers, esters, ethers,**

salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

2. **3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-1H-benzimidazol-2-one (other names: chlorphine; 1-[1-[1-(4-chlorophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
3. **3-[3-[1-[1-(4-chlorophenyl)ethyl]piperidin-4-yl]-2-oxobenzimidazol-1-yl]propanenitrile (other names: cycchlorphine; N-propionitrile chlorphine)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
4. **[3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-yl] acetate (other names: 4-acetoxy-N-methyl-N-ethyltryptamine, 4-acetoxy-MET, 4-AcO-MET)**, its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
5. **1-(4-bromophenyl)-2-pyrrolidin-1-ylpentan-1-one (other names: 4-bromo-alpha-pyrrolidinovalerophenone, 4-bromo-alpha-PVP)**, its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
6. **1-[1-(3-methylphenyl)cyclohexyl]piperidine (other names: 3-methyl phencyclidine, 3-methyl PCP)**, its salts, isomers (optical, position, and geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

MEETING ADJOURNED:

9:03AM

Caroline Juran, RPh
Executive Director

Date